Human Genetics

, Volume 102, Issue 5, pp 591–597 | Cite as

Gross deletions of the neurofibromatosis type 1 (NF1) gene are predominantly of maternal origin and commonly associated with a learning disability, dysmorphic features and developmental delay

  • M. Upadhyaya
  • M. Ruggieri
  • J. Maynard
  • M. Osborn
  • C. Hartog
  • S. Mudd
  • M. Penttinen
  • I. Cordeiro
  • M. Ponder
  • B. A. J. Ponder
  • M. Krawczak
  • D. N. Cooper
Original Investigation

Abstract

Mutation screening in neurofibromatosis type 1 (NF1) families has long been hampered by the complexity of the NF1 gene. By using a novel multi-track screening strategy, 67 NF1 families (54 two-generation, 13 three-generation) with a de novo mutation in the germline of the first generation were studied with two extragenic and 11 intragenic markers. The pathological lesion was identified in 31 cases. Loss of heterozygosity (LOH) in the affected individual revealed a gross gene deletion in 15 of the two-generation families; in 12 (80%) of them, the deletion was maternally derived. Eleven patients with a gross deletion exhibited developmental delay, ten had dysmorphic features and six manifested a learning disability. No gross deletion was apparent in any of the 13 three-generation families, suggesting that such lesions are subject to more intense selection. In these families, the new mutation was of paternal origin in 11 kindreds and the underlying mutational event could be characterised in three of them.

Keywords

Developmental Delay Mutational Event Gene Deletion Neurofibromatosis Learning Disability 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • M. Upadhyaya
    • 1
  • M. Ruggieri
    • 2
  • J. Maynard
    • 1
  • M. Osborn
    • 1
  • C. Hartog
    • 1
  • S. Mudd
    • 1
  • M. Penttinen
    • 3
  • I. Cordeiro
    • 4
  • M. Ponder
    • 5
  • B. A. J. Ponder
    • 5
  • M. Krawczak
    • 1
  • D. N. Cooper
    • 1
  1. 1.Institute of Medical Genetics, University of Wales College of Medicine, Heath Park, Cardiff CF4 4XN, UKGB
  2. 2.Department of Clinical Genetics, John Radcliffe Hospital, Oxford OX3 7LJ, UKGB
  3. 3.Cinical Genetics Unit, Turku University Central Hospital, Turku, FinlandFI
  4. 4.Uniclade de Genetica, Hospital Santa Maria, 1699 Lisbon Coxed, PortugalPT
  5. 5.CRC Human Cancer Genetics Group, Department of Pathology, University of Cambridge, Cambridge CB2 1QP, UKGB

Personalised recommendations